Non-small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) originates from lung tissue and typically grows and spreads at a slower rate compared to small cell lung cancer. Alfa Cytology is a world leader in the research of lung cancer. With our extensive experience and advanced platform, we can provide the best solutions for NSCLC.
Introduction to Non-small Cell Lung Cancer
Non-small cell lung cancer accounts for approximately 80% to 85% of lung cancer. According to their origin from different types of lung cells, the main subtypes are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Meanwhile, due to its similar treatment and prognosis, it is classified as non-small cell lung cancer.
Adenocarcinoma
Lung adenocarcinoma begins with epithelial cells in the lungs and is the most common type of non-small cell lung cancer.
Squamous Cell Carcinoma
Squamous cell carcinoma begins with flat squamous cells inside the lung airways and is usually associated with a history of smoking.
Large Cell Carcinoma
Large cell carcinoma can appear in any part of the lungs. It often grows and spreads rapidly, making treatment more difficult.
Therapy Development for Non-small Cell Lung Cancer
The development of therapies for NSCLC typically includes surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. NSCLC is usually caused by gene mutation or alteration, such as EGFR, ALK, ROS1, or KRAS mutations.
- Targeted therapy: Targeted therapy development typically targets gene mutations or abnormal proteins in cancer cells, such as EGFR inhibitors (e.g., erlotinib, osimertinib) or ALK inhibitors (e.g., crizotinib, alectinib). They are effective for specific subgroups of NSCLC with specific gene mutations.
- Immunotherapy: Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, can enhance the immune system's ability to recognize and attack cancer cells. They have completely changed the therapy methods for non-small cell lung cancer, especially for the advanced stage.
The following are a few examples of pharmaceutical companies and their pipeline development related to NSCLS. The field of therapy for NSCLC is developing rapidly.
| Targets |
Therapeutics |
Company |
Molecule Type |
Phase |
| TK |
Entrectinib |
Genentech |
Small molecule |
|
| LAG-3 |
Favezelimab (MK-4280) |
Merck |
Monoclonal antibody |
|
| TGF-β1 |
ABBV-151 |
Abbvie |
Humanized monoclonal antibody inhibitor |
|
| cMet |
Telisotuzumab vedotin (ABBV-399) |
Abbvie |
Antibody-drug conjugate |
|
Our Services
Due to the complexity of NSCLC, there are many challenges in developing effective therapies, such as tumor heterogeneity, genetic complexity and variability, and breaking through the blood-brain barrier. Therefore, Alfa Cytology is working on providing one-stop solutions, including but not limited to the following.
Models of NSCLC
Models of NSCLC are used to study the biology of the disease, its progression, treatment response, and the development of new therapies. Alfa Cytology is a leading biological contract research organization (CRO). We have many years of experience in building NSCLC tumor models. Our company offers several popular NSCLC models, including but not limited to the following. Each model has its characteristics and applications.
Xenogeneic Models
- Lung large cell carcinoma model
- Adenocarcinoma model
- squamous cell carcinoma model
Alfa Cytology is committed to the research and study of lung cancer and provides one-stop services. Our cancer experts have many years of experience in the development of the latest therapies for NSCLC. If you are interested in our service, please contact us for more information.
For research use only.
Related Services
